Evaluation of EuroQol Valuation Technology (EQ-VT) Designs to Generate National Value Sets: Learnings from the Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study.

EQ-5D extended design health technology assessment model prediction performance predictive accuracy time tradeoff valuation value set

Journal

Medical decision making : an international journal of the Society for Medical Decision Making
ISSN: 1552-681X
Titre abrégé: Med Decis Making
Pays: United States
ID NLM: 8109073

Informations de publication

Date de publication:
08 2023
Historique:
medline: 14 8 2023
pubmed: 22 7 2023
entrez: 22 7 2023
Statut: ppublish

Résumé

Countries develop their EQ-5D-5L value sets using the EuroQol Valuation Technology (EQ-VT) protocol. This study aims to assess if extension in the conventional EQ-VT design can lead to development of value sets with improved precision. A cross-sectional survey was undertaken in a representative sample of 3,548 adult respondents, selected from 5 different states of India using a multistage stratified random sampling technique. A novel extended EQ-VT design was created that included 18 blocks of 10 health states, comprising 150 unique health states and 135 observations per health state. In addition to the standard EQ-VT design, which is based on 86 health states and 100 observations per health state, 3 extended designs were assessed for their predictive performance. The extended designs were created by 1) increasing the number of observations per health state in the design, 2) increasing the number of health states in the design, and 3) implementing both 1) and 2) at the same time. Subsamples of the data set were created for separate designs. The root mean squared error (RMSE) and mean absolute error (MAE) were used to measure the predictive accuracy of the conventional and extended designs. The average RMSE and MAE for the standard EQ-VT design were 0.055 and 0.041, respectively, for the 150 health states. All 3 types of design extensions showed lower RMSE and MAE values as compared with the standard design and hence yielded better predictive performance. RMSE and MAE were lowest (0.051 and 0.039, respectively) for the designs that use a greater number of health states. Extending the design with inclusion of more health states was shown to improve the predictive performance even when the sample size was fixed at 1,000. Although the standard EQ-VT design performs well, its prediction accuracy can be further improved by extending its design. The addition of more health states in EQ-VT is more beneficial than increasing the number of observations per health state. The EQ-5D-5L value sets are developed using the standardized EuroQol Valuation Technology (EQ-VT) protocol. This is the first study to empirically assess how much can be gained from extending the standard EQ-VT design in terms of sample size and/or health states. It not only presents useful insights into the performance of the standard design of the EQ-VT but also tests the potential extensions in the standard EQ-VT design in terms of increasing the health states to be directly valued as well as the number of observations recorded to predict the utility value of each of these health states.The study demonstrates that the standard EQ-VT design performs good, and an extension in the design of the standard EQ-VT can lead to further improvement in its performance. The addition of more health states in EQ-VT is more beneficial than increasing the number of observations per health state. Extending the design with inclusion of more health states marginally improves the predictive performance even when the sample size was fixed at 1,000.The findings of the study will streamline the systematic process for generating precise EQ-5D-5L value sets, thus facilitating the conduct of credible, transparent, and robust outcome valuation in health technology assessments.

Identifiants

pubmed: 37480281
doi: 10.1177/0272989X231180134
pmc: PMC10422850
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

692-703

Références

Indian J Med Res. 2020 Nov;152(5):444-447
pubmed: 33707385
Value Health. 2019 Jan;22(1):23-30
pubmed: 30661630
Pharmacoecon Open. 2018 Mar;2(1):1-3
pubmed: 29464668
Value Health. 2017 Mar;20(3):466-473
pubmed: 28292492
Value Health. 2017 Apr;20(4):662-669
pubmed: 28408009
Pharmacoeconomics. 2016 Oct;34(10):993-1004
pubmed: 27084198
Br Med Bull. 2010;96:5-21
pubmed: 21037243
Value Health. 2022 Jul;25(7):1218-1226
pubmed: 35779943
J Mark Access Health Policy. 2019 Aug 22;7(1):1648973
pubmed: 31489150
Soc Sci Med. 2005 Apr;60(7):1571-82
pubmed: 15652688
Med Care. 2017 Jul;55(7):e51-e58
pubmed: 25521503
Health Qual Life Outcomes. 2014 Mar 24;12:42
pubmed: 24661350
Appl Health Econ Health Policy. 2021 Jan;19(1):29-44
pubmed: 32661846
Value Health. 2018 Apr;21(4):456-461
pubmed: 29680103
BMJ Open. 2020 Nov 20;10(11):e039517
pubmed: 33444194
BMJ Glob Health. 2017 Jun 26;2(2):e000259
pubmed: 29225927
Qual Life Res. 2016 Dec;25(12):2997-3008
pubmed: 27444779
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Value Health. 2019 Jan;22(1):38-44
pubmed: 30661632
Soc Sci Med. 2002 Mar;54(6):919-29
pubmed: 11996025
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4016-23
pubmed: 16249475
Br J Psychiatry. 2014 Sep;205(3):236-43
pubmed: 24855127
Value Health. 2019 Jul;22(7):829-836
pubmed: 31277831
Pharmacoeconomics. 2017 Nov;35(11):1153-1165
pubmed: 28695543
Med Decis Making. 2019 Jul;39(5):605-616
pubmed: 31257997
Value Health. 2019 Nov;22(11):1295-1302
pubmed: 31708067
Int J Gynecol Cancer. 2020 Dec;30(12):1887-1892
pubmed: 32788265
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137
pubmed: 28194657
Appl Health Econ Health Policy. 2018 Apr;16(2):187-194
pubmed: 29047072
Diabet Med. 2011 Apr;28(4):395-413
pubmed: 21392061
Med Care. 1995 Apr;33(4 Suppl):AS255-63
pubmed: 7723454
Pharmacoeconomics. 2007;25(5):365-84
pubmed: 17488136
Glob Health Action. 2018;11(1):1527556
pubmed: 30326795
J Clin Epidemiol. 1999 Apr;52(4):293-301
pubmed: 10235169

Auteurs

Gaurav Jyani (G)

Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Zhihao Yang (Z)

Guizhou Medical University, Guiyang, People's Republic of China.

Atul Sharma (A)

Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Aarti Goyal (A)

Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Elly Stolk (E)

EuroQol Research Foundation, Rotterdam, South Holland, the Netherlands.

Fredrick Dermawan Purba (FD)

Department of Developmental Psychology, Faculty of Psychology, Universitas Padjadjaran, Bandung, Jawa Barat, Indonesia.

Sandeep Grover (S)

Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Manmeet Kaur (M)

Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Shankar Prinja (S)

Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH